PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Pregabalin - Epilepsy
PAD Profile : Pregabalin - Epilepsy
Brand Names Include :
Lyrica
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Eslicarbazepine acetate
- Carbamazepine
- Clobazam
- Lacosamide
- Clonazepam
- Perampanel
- Ethosuximide
- Felbamate
- Rufinamide
- Gabapentin
- Stiripentol
- Lamotrigine
- Zonisamide
- Levetiracetam
- Oxcarbazepine
- Phenobarbital
- Piracetam
- Phenytoin
- Topiramate
- Sodium valproate
- Brivaracetam
- Sodium valproate
- Cannabidiol
- Vigabatrin
- Cenobamate
- Primidone
- Tiagabine
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (National)
01 April 2021
Safety Information
01 August 2023
Committee Recommendations
Date
Committee Name
Narrative
06 March 2019
Surrey Medicines Commissioners Group
From 1st April 2019 both pregabalin and gabapentin will be classified as a schedule 3 Controlled Drug. As such, the arrangements through which patients obtain these medicines will change.
The Surrey Medicines Commissioners Group have developed a patient template letter for local adaption - see below.
In addition, NHSE have produced a patient hand-out that is also available below
04 April 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN supported the principles of switching from brand to generic medications (not recommended in the elderly) as per national guidelines in September 2013 and the proposed place in therapy of the anti-epileptic drugs which is based on NICE guidance was also discussed at that time. Transfer of care documents will be considered at a future PCN.
Please note the MHRA categorisations for each drug in the attached guidance (updated January 2014) and in the link below
Prescribers are reminded to undertake a proportionate risk benefit assessment prior to prescribing Pregabalin or Gabapentin for patients with a known or suspected propensity to misuse.
Associated BNF Codes
04. Central Nervous System
04.08.01. Control of epilepsy